Luye Pharma Group Ltd. (LYPHF)
OTHER OTC:LYPHF
Want to see LYPHF full AI Analyst Report?
LYPHF Stock Chart & Stats
$0.40
$0.03(11.09%)
At close: 4:00 PM EST
$0.40
$0.03(11.09%)
Day’s Range― - ―
52-Week Range$0.27 - $0.41
Previous CloseN/A
Volume1.00K
Average Volume (3M)0.00
Market Cap
$1.28B
Enterprise Value$13.83B
Total Cash (Recent Filing)$8.88B
Total Debt (Recent Filing)$9.42B
Price to Earnings (P/E)8.3
Beta0.25
Next Earnings
Aug 27, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.15
Shares Outstanding3,994,515,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)0.60
Price to Sales (P/S)1.56
P/FCF Ratio12.29
Enterprise Value/Market Cap10.78
Enterprise Value/Revenue2.21
Enterprise Value/Gross Profit3.35
Enterprise Value/Ebitda7.31
Forecast
1Y Price Target
$0.55Price Target Upside37.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)$886.29M
Bulls Say, Bears Say
Bulls Say
High And Sustainable MarginsConsistently high gross and EBITDA margins indicate durable product-level economics and potential pricing or formulation advantages from drug-delivery technology. Such margin strength supports reinvestment in R&D and commercialization and cushions against cost inflation over the medium term.
Improving Leverage And Balance SheetA materially lower debt-to-equity ratio increases financial flexibility for launches, partnerships, and M&A without excessive interest drag. Improved leverage reduces refinancing risk and gives the company capacity to fund strategic initiatives over the next 2-6 months and beyond.
Rebound To Positive Free Cash FlowThe move to positive operating and free cash flow reflects improved cash generation capacity after prior outflows. Reliable free cash enables sustained investment in commercial rollouts, supports debt paydown or licensing deals, and reduces dependence on external financing.
Bears Say
Sharp 2025 Revenue DeclineA large single-year revenue contraction signals potential demand loss, product cycle issues, or competitive displacement. This undermines confidence in top-line durability, risks underutilized capacity, and can pressure margins and investment plans until growth stabilizes or new launches compensate.
Volatile Free Cash Flow HistoryHistorical swings in free cash flow reduce predictability of funding for R&D, marketing, and capital projects. Volatility increases the likelihood of episodic financing needs or delayed investments, complicating planning and weakening confidence in sustained cash returns to stakeholders.
Low Return On EquityA low ROE despite healthy margins implies capital is not being deployed efficiently into value-accretive growth. Over time this can limit shareholder value creation, indicate underperforming assets or overcapitalization, and pressure management to improve capital allocation.
Luye Pharma Group News
LYPHF FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was $0.27 and its highest was $0.41 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is $1.28B.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 114 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Mar 30, 2026. The company reported $0.012 earnings per share for the quarter, the consensus estimate of $0.012 by $0.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of $0.008 which represents an annual dividend yield of N/A. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is <0.01.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of $0.012 in its last earnings report, expectations of $0.012. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in LYPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Luye Pharma Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.55 (37.84% Upside)
$0.55 (37.84% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.79%
12-Months-Change
Fundamentals
Return on Equity
3.99%
Trailing 12-Months
Asset Growth
15.79%
Trailing 12-Months
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
LYPHF Stock 12 Month Forecast
Average Price Target
$0.55
▲(37.84% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Ownership Overview
―
Insiders
2.36% Mutual Funds
― Other Institutional Investors
94.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---